Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an
investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically
mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options,
the treatments are associated with short response duration, thus this condition is largely
incurable. This investigational drug may offer less toxicity than standard treatments and
have better tumor specific targeting.